1. Market Research
  2. > Enterococcus Infections – Pipeline Review, H1 2013

Enterococcus Infections – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 106 pages

Enterococcus Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Enterococcus Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Infections. Enterococcus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Enterococcus Infections.
- A review of the Enterococcus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterococcus Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Enterococcus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterococcus Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Enterococcus Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Enterococcus Infections Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Enterococcus Infections 10
Enterococcus Infections Therapeutics under Development by Companies 12
Enterococcus Infections Therapeutics under Investigation by Universities/Institutes 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Enterococcus Infections Therapeutics - Products under Development by Companies 19
Enterococcus Infections Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Enterococcus Infections Therapeutics Development 22
Dainippon Sumitomo Pharma Co., Ltd. 22
Rib-X Pharmaceuticals, Inc. 23
Aphios Corporation 24
Wockhardt Limited 25
Alchemia Limited 26
Immtech Pharmaceuticals, Inc. 27
Lorus Therapeutics Inc 28
NovaBay Pharmaceuticals, Inc. 29
Oragenics, Inc. 30
SIGA Technologies, Inc. 31
Evolva SA 32
Aquapharm Biodiscovery Limited 33
MicuRx Pharmaceuticals, Inc. 34
Nabriva Therapeutics AG 35
Ancora Pharmaceuticals Inc. 36
Trius Therapeutics, Inc. 37
Lytix Biopharma AS 38
Ascenion GmbH 39
TAXIS Pharmaceuticals, Inc. 40
Enterococcus Infections - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
LOR-220 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Antibiotic Program - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Sortase Inhibitor - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
auriclosene - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
MU-1140 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
BC-3781 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
RX-04 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
EnteroVAX - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
AVX-13616 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
PM-181104 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
tedizolid phosphate - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
MRX-I - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Marinus - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
WCK-4086 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
MRX-II - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Antibiotic Program - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
SLP-0905 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
SLP-0904 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
MGB-BP-3 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Second Generation Oxas - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
EV-035 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
AQP-182 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
MU-1140-S - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
NAI-107 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Azachryseniums Series - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
MGB-BP-3 IV - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
SM-295291 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
SM-369926 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Berberine Derivatives - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
Antibacterial Compounds For Gram Possitive Bacterial Infections - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
Tetramic Acid Analogs - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
Closthioamide - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
7-O-Malonyl Macrolactin A - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
SecATPase Inhibitors - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
Enterococcus Infections Therapeutics - Drug Profile Updates 87
Enterococcus Infections Therapeutics - Dormant Products 100
Enterococcus Infections - Product Development Milestones 101
Featured News and Press Releases 101
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 101
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 101
Aug 14, 2012: Lorus Therapeutics Announces Issuance Of Patent In Japan For Antimicrobial Drug LOR-220 102
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 102
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 103
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 103
Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106



List of Tables

Number of Products Under Development for Enterococcus Infections, H1 2013 10
Products under Development for Enterococcus Infections - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Mid Clinical Stage Development, H1 2013 16
Comparative Analysis by Early Clinical Stage Development, H1 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Development by Companies, H1 2013 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2013 21
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 22
Rib-X Pharmaceuticals, Inc., H1 2013 23
Aphios Corporation, H1 2013 24
Wockhardt Limited, H1 2013 25
Alchemia Limited, H1 2013 26
Immtech Pharmaceuticals, Inc., H1 2013 27
Lorus Therapeutics Inc, H1 2013 28
NovaBay Pharmaceuticals, Inc., H1 2013 29
Oragenics, Inc., H1 2013 30
SIGA Technologies, Inc., H1 2013 31
Evolva SA, H1 2013 32
Aquapharm Biodiscovery Limited, H1 2013 33
MicuRx Pharmaceuticals, Inc., H1 2013 34
Nabriva Therapeutics AG, H1 2013 35
Ancora Pharmaceuticals Inc., H1 2013 36
Trius Therapeutics, Inc., H1 2013 37
Lytix Biopharma AS, H1 2013 38
Ascenion GmbH, H1 2013 39
TAXIS Pharmaceuticals, Inc., H1 2013 40
Assessment by Monotherapy Products, H1 2013 41
Assessment by Stage and Route of Administration, H1 2013 43
Assessment by Stage and Molecule Type, H1 2013 45
Enterococcus Infections Therapeutics - Drug Profile Updates 87
Enterococcus Infections Therapeutics - Dormant Products 100



List of Figures

Number of Products under Development for Enterococcus Infections, H1 2013 10
Products under Development for Enterococcus Infections - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Mid Clinical Stage Products, H1 2013 16
Early Clinical Stage Products, H1 2013 17
Discovery and Pre-Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 41
Assessment by Route of Administration, H1 2013 42
Assessment by Stage and Route of Administration, H1 2013 43
Assessment by Molecule Type, H1 2013 44
Assessment by Stage and Molecule Type, H1 2013 45

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.